* ISOPTO-MAXITROL Sterile Eye (Ophthalmic) Preparation. 5 ml Drop-Trainer Dispenser. |
* Composition (Ingredients): |
– Active: Neomycin (present as Sulfate) 3.5 mg / mL, Polymyxin B Sulfate 6,000 units/mL, Dexamethasone 0.1%. |
– Vehicle: Hydroxypropyl Methylcellulose (4,000 cps) 0.5%. |
– Preservative: Benzalkonium Chloride 0.004%. |
* Indications: |
& Eye: In the management of infectious ocular inflammations produced by organisms which are sensitive |
& to the antibiotics, Neomycin Sulfate and Polymyxin B sulfate. Acute or chronic nonpurulent conjunctivitis, |
& blepharoconjunctivitis and keratoconjunctivitis; nonspecific superficial keratitis; deep keratitis; acne |
& rosacea keratitis; iridocyclitis mild acute iritis; recurrent marginal ulceration and corneal ulcer (use with |
& care in those diseases causing thining of cornea because of the danger of proliferation); nonpurulent |
& blepharitis; scleritis; episcleritis; scleroconjunctivitis; herpes zoster ophthalmicus (do not use in Herpes |
& simplex); and post-operatively to aid in the prevention of ophthalmic cases of infections. |
* Contraindications: |
& This drug is contraindicated in tuberculosis, fungal and most viral lesions of eye (herpes simplex/dentritic |
& keratitis); varicella; acute purulent conjunctivitis and acute purulent blepharitis, aural fungal infection. |
* Precautions: |
– Extended use of topical steroid therapy may cause increased intraocular pressure in certain individuals. |
& It is advisable that intraocular pressure be checked frequently. |
– In those diseases causing thinning of the cornea, perforation has been known to occur with the use of |
& topical steroids. |
– Prolonged use may result in overgorwth of non-susceptible organisms, including fungi. Appropriate measures |
& should be taken when this occurs. A few individuals may be sensitive to one or more components of this |
& product. If any reactions indicating sensitivity are observed, discontinue use. |
– Although topical steroids have not been reported to have an adverse effect on pregnancy, the safety of |
& their use in pregnancy has not absolutely been established. Therefore it is advisable not to use this product |
& for long-term treatments of pregnant patients. |
* Dosage and Administration: |
& Eye: one or two drops topically in the conjunctival sac(s) 4 to 6 times daily. Dosage may be reduced after |
& 3 to 4 days when satisfactory improvement has been obtained. Treatment should be repeated as long as |
& necessary following physician’s advice. |
* Shake Well Before Using. |
* Store upright. Do not store above 25 degrees C. Do not refrigerate or freeze. |
* ALCON-COUVREUR – Belgium. المستوردون: الشركة المتحدة للتجارة والتوزيع |
Weight | 100 kg |
---|
Q & A
Ask a question
Your question will be answered by a store representative or other customers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Thank you for the question!
Your question has been received and will be answered soon. Please do not submit the same question again.
Error
An error occurred when saving your question. Please report it to the website administrator. Additional information:
Add an answer
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Thank you for the answer!
Your answer has been received and will be published soon. Please do not submit the same answer again.
Error
An error occurred when saving your answer. Please report it to the website administrator. Additional information: